Category Archives: Proton Pump Inhibitors

Featured Stories

Federal Judge Certifies Medtronic Infuse Shareholder Class Action Lawsuit

A shareholder lawsuit alleging Medtronic Inc. illegally promoted the off-label use of its Infuse bone growth product has been granted class action status by U.S. District Judge Paul Magnuson of Minnesota. According to a report from Law360.com, the Medtronic Infuse off-label promotion lawsuit was filed by several institutional investors on ...

Read More

Actos, Avandia May Up Risk for Diabetic Macular Edema

A West Virginia man fitted with a metal-on-metal version of DePuy Orthopaedics’ Pinnacle Hip Implant System has filed suit against the company and its parent, Johnson & Johnson, alleging the device caused him to suffer pain and elevated cobalt levels. The Plaintiff is being represented by the national law ...

Read More

Medtronic Settles Charges Over Kickbacks To Doctors

Medical device giant, Medtronic Inc., is settling charges over kickbacks to doctors. The firms just agreed to pay $23.5 million to settle claims it paid physicians kickbacks in exchange for their use of its pacemakers and defibrillators, according to a U.S. Justice Department announcement yesterday. The company was accused of seeking ...

Read More

Bisphosphonate Study Confirms Atypical Thigh Fracture Risk

New research has confirmed the link between bisphoshonates, such as Fosamax, and atypical femur fractures, a type of thigh fracture that occurs spontaneously, without any major leg injury. The study, published in the Archives of Internal Medicine, also found that the risk of atypical thigh fractures increases the longer a ...

Read More

First DePuy ASR Hip Implant Lawsuits Head to Trial in December, January

The first trials involving lawsuits filed against DePuy Orthopaedics by recipients of its recalled ASR Hip Implants will begin later this year, and early next year. The first is slated to start on December 3, 2012 in state court in Las Vegas, Nevada. A second DePuy ASR hip implant lawsuit ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Medtronic Infuse Studies Faulted for Downplaying Side Effects

Medtronic Inc.’s published studies for its Infuse bone graft product may have downplayed serious side effects, according to an analysis published last year in The Spine Journal. The study, which drew on U.S. Food & Drug Administration (FDA) documents and other data sources, suggests that up to half of ...

Read More

Federal Judge Certifies Medtronic Infuse Shareholder Class Action Lawsuit

A shareholder lawsuit alleging Medtronic Inc. illegally promoted the off-label use of its Infuse bone growth product has been granted class action status by U.S. District Judge Paul Magnuson of Minnesota. According to a report from Law360.com, the Medtronic Infuse off-label promotion lawsuit was filed by several institutional investors on ...

Read More

Lawsuit Alleges Bi-Lateral DePuy ASR Hip Implant Resulted in Elevated Chromium and Cobalt Levels, Need for Revision Surgery

DePuy Orthopaedics and its parent, Johnson & Johnson, continue to be named in lawsuits by metal-on-metal hip replacement recipients who suffered severe injuries, including elevated chromium and cobalt levels, allegedly due to recalled ASR hip implant devices. Most recently, the national law firm of Parker Waichman LLP filed suit on ...

Read More

FDA Metal-On-Metal Hip Replacement Investigation Is Flawed, Researchers Say

The U.S. Food & Drug Administration’s (FDA) metal-on-metal hip replacement investigation is flawed, according to researchers.

Read More

Popular Heartburn Medications Linked to Increased Risk of Death

Drugs to relieve heartburn and acid-reflux are among the best selling drugs in the country, used by millions of Americans annually in both prescription and non-prescription strength. Excess acid can cause stomach ulcers and damage to the esophagus. A reduction … Continue reading

Posted in Health Concerns, Pharmaceuticals, Proton Pump Inhibitors |

Popular Acid Reflux Medication Nexium Linked to Kidney Issues

Acid Reflux Medication Nexium Linked to Kidney Issues

Recent revelations about Nexium have uncovered kidney side effects in one of the most frequently prescribed treatments for excess stomach acid. Nexium is the brand name for esomeprazole, manufactured by Astra Zeneca. Nexium conditions such as gastroesophageal reflux or Zollinger-Ellison … Continue reading

Posted in Nexium, Pharmaceuticals, Proton Pump Inhibitors | Tagged , , , , , , , , , |

Nexium, Other PPIs and the Risk of Kidney Side Effects

Nexium, Other PPIs and the Risk of Kidney Side Effects

Nexium, Prilosec and Prevacid are part of a class of medications known as proton pump inhibitors (PPIs). They are used to relieve heartburn and acid reflux by lowering the amount of acid produced by the stomach. Recent studies suggest that … Continue reading

Posted in Nexium, Pharmaceuticals, Proton Pump Inhibitors | Tagged , , , , , , , , , , , |

Research Suggests Long-Term PPI Use is Linked to Kidney Damage

Research Suggests Long-Term PPI Use Linked to Kidney Damage

Two studies published this year evaluated the risk of kidney damage associated with proton pump inhibitors (PPIs). PPIs, which treat heartburn and acid reflux by lowering the amount of stomach acid produced, include Prilosec, Nexium and Prevacid. The studies suggest … Continue reading

Posted in Nexium, Pharmaceuticals, Proton Pump Inhibitors | Tagged , , , , , , , , , , , , , , , |

Increased Dementia Risk Linked to Heartburn Drugs Linked to Use of Proton Pump Inhibitors for Heartburn

New research suggests that the use of certain drugs for gastric reflux or peptic ulcers creates an increased risk for dementia in elderly patients. The class of drugs—proton pump inhibitors (PPIs)—includes Prevacid (lansoprazole), Nexium (esomeprazole), and Prilosec (omeprazole), HealthDay reports.

Posted in Defective Products, Health Concerns, Nexium, Pharmaceuticals, Proton Pump Inhibitors |

Widely Used Heartburn Drugs Linked to Increased Risk for Dementia

Researchers say repeated use certain drugs for gastric reflux or peptic ulcers is linked to a higher risk for dementia among patients in Germany. The class of drugs—proton pump inhibitors (PPIs)—includes Prevacid (lansoprazole), manufactured by Novartis, Nexium (esomeprazole) and Prilosec … Continue reading

Posted in Health Concerns, Pharmaceuticals, Proton Pump Inhibitors |

Common Heartburn Drugs May Increase Risk for Kidney Disease

Proton-pump-inhibitors

Proton pump inhibitors (PPIs)—widely used heartburn medicines—may increase the risk for kidney disease. PPIs are sold under brand names, including Nexium, Prevacid and Prilosec, in both prescription and over-the-counter formulas. Proton pump inhibitors (PPIs) greatly reduce the amount of acid … Continue reading

Posted in Health Concerns, Pharmaceuticals, Proton Pump Inhibitors | Tagged , , , , , |

Study Shows Proton Pump Inhibitors May Increase Heart Attack Risk

Proton Pump Inhibitors May Increase Heart Attack Risk

  A data-mining study published on June 10 in PLOS One shows that people who take proton pump inhibitor drugs for gastroesophageal reflux disease (GERD) are at increased risk for heart attacks. The study evaluated data for 2.9 million patients … Continue reading

Posted in Health Concerns, Pharmaceuticals, Proton Pump Inhibitors | Tagged , , , |

Stomach Acid Medications May Increase Risk of Vitamin Deficiency

stomach-aid-vitamin-deficiency

Some drugs widely used to control stomach acid may increase the risk of a serious vitamin deficiency, a new study suggests. A research team found that people who were diagnosed with vitamin B12 deficiency were more likely to be taking … Continue reading

Posted in Health Concerns, Nexium, Pharmaceuticals, Proton Pump Inhibitors |

Kidney transplant rejections higher among those prescribed PPI acid-blockers

A retrospective study of kidney transplant patients found that those taking Proton Pump Inhibitor (PPI) drugs in conjunction with another drug in the year after their surgery were more likely to experience rejection. According to a report at RenalandUrologyNews.com on … Continue reading

Posted in Pharmaceuticals, Proton Pump Inhibitors | Tagged , , |

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.